‘Global judicial support network set to launch soon’
Judge Kaly Kaul KC revealed that the new network aims to enable judges to discuss concerns, share support, and ensure each other's wellbeing globally
FILE PHOTO: Kaly Kaul KC at The GG2 Leadership and Diversity Awards 2022 held at Park Plaza Westminster Bridge Hotel in London. (Photo: Edward Lloyd/Alpha Press)
Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
AN Asian circuit judge in England and Wales has said that a global support network designed to provide a secure and private platform for judges worldwide will be launched soon.
Judge Kaly Kaul KC revealed that the new network aims to enable judges to discuss concerns, share support, and ensure each other's wellbeing globally.
Speaking at the London Criminal Courts Solicitors’ Association annual meeting this week, she has urged to help each other as the global judiciary is facing growing concerns regarding mental health and professional challenges.
She had previously taken legal action against senior judges and court officials due to mishandling of her grievances, an experience that highlighted the need for a more robust support system for judges in demanding roles.
The judiciary of England and Wales issued a 'statement of expected behaviour' last year following research commissioned by the lord chief justice that highlighted instances of reported bullying, harassment, and discrimination. A survey by the UN Office on Drugs and Crime’s Global Judicial Integrity Network confirmed that these issues extend beyond the UK, affecting judicial systems worldwide.
The steering committee for this support network includes judges from a diverse range of countries, including Tonga, the US, Uganda, Bangladesh, Nauru, Sri Lanka, and England and Wales.
She said, “The main issues facing judges across the globe are remarkably similar, and judges need a safe space to raise concerns.”
One of the network’s primary initiatives is to compile a directory of mental health professionals—including psychiatrists, psychologists, psychotherapists, and counsellors—whom judges can approach for support.
Confidentiality is a core principle, with ‘triage judges’ designated to connect individuals with the right assistance while maintaining complete discretion.
Kaul explains, “So, if Judge X has a problem, they could be put in touch with Judge K in Uganda for mentoring, and a senior psychologist in Trinidad, Australia, or the UK for psychological support. No one need to know, except the triage judges.”
The network also intends to produce annual reports, identifying positive practices and ongoing challenges in judicial wellbeing.
"We hope this will support the UN Declarations, the Bangalore and Nauru principles, and result in a stronger, healthier, fairer and safer judiciary internationally, in the knowledge that the eyes of other jurisdictions are open and watching," she was quoted as saying.
The Bangalore Principles set guidelines for judges' ethical conduct, while the Nauru Declaration on Judicial Wellbeing outlines principles and commitments to support the judiciary's wellbeing and integrity. This declaration was officially adopted at the Regional Judicial Conference on Integrity and Judicial Wellbeing in July 2024.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.